Jennifer Vermette

1.3k total citations
14 papers, 964 citations indexed

About

Jennifer Vermette is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jennifer Vermette has authored 14 papers receiving a total of 964 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 7 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jennifer Vermette's work include HER2/EGFR in Cancer Research (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Jennifer Vermette is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). Jennifer Vermette collaborates with scholars based in United States, Spain and Japan. Jennifer Vermette's co-authors include Richat Abbas, Christine Powell, Charles Zacharchuk, Ahmad Awada, Robert Paridaens, Luc Dirix, Anantbhushan Ranade, Antoinette R. Tan, Kathleen Turnbull and Shunchang Jiao and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Jennifer Vermette

14 papers receiving 937 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jennifer Vermette United States 8 712 334 305 304 182 14 964
Martina Uttenreuther‐Fischer Germany 16 890 1.3× 350 1.0× 666 2.2× 214 0.7× 119 0.7× 32 1.1k
Jonathan Golas United States 6 818 1.1× 438 1.3× 305 1.0× 311 1.0× 150 0.8× 8 1.1k
Guorong Yang China 8 611 0.9× 369 1.1× 181 0.6× 269 0.9× 104 0.6× 19 920
Glenn Spehar United States 7 806 1.1× 499 1.5× 234 0.8× 340 1.1× 119 0.7× 8 1.2k
Anantbhushan Ranade India 11 557 0.8× 228 0.7× 286 0.9× 202 0.7× 84 0.5× 32 795
Kathleen Turnbull United States 11 599 0.8× 292 0.9× 268 0.9× 225 0.7× 268 1.5× 21 999
Devika Gajria United States 12 536 0.8× 322 1.0× 136 0.4× 190 0.6× 63 0.3× 31 867
Ruth Seggewiss‐Bernhardt Germany 12 409 0.6× 434 1.3× 232 0.8× 91 0.3× 152 0.8× 19 889
K. Papadopoulos United States 16 540 0.8× 598 1.8× 215 0.7× 121 0.4× 90 0.5× 56 1.1k
Maria G. Olivares United States 7 780 1.1× 767 2.3× 381 1.2× 317 1.0× 93 0.5× 9 1.3k

Countries citing papers authored by Jennifer Vermette

Since Specialization
Citations

This map shows the geographic impact of Jennifer Vermette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Vermette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Vermette more than expected).

Fields of papers citing papers by Jennifer Vermette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jennifer Vermette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Vermette. The network helps show where Jennifer Vermette may publish in the future.

Co-authorship network of co-authors of Jennifer Vermette

This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Vermette. A scholar is included among the top collaborators of Jennifer Vermette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Vermette. Jennifer Vermette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Steinberg, Gary D., Neal D. Shore, Joan Palou Redorta, et al.. (2024). CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer. Future Oncology. 20(14). 891–901. 15 indexed citations
3.
4.
Wang, Eunice S., Richard Aplenc, Deborah Chirnomas, et al.. (2020). Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma. 61(8). 1965–1973. 11 indexed citations
5.
Wang, Eunice S., Richard Aplenc, Deborah Chirnomas, et al.. (2018). Safety of Gemtuzumab Ozogamicin As Monotherapy or Combination Therapy in an Expanded-Access Protocol for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 132(Supplement 1). 3979–3979. 1 indexed citations
6.
Wainberg, Zev A., María Alsina, Heloisa P. Soares, et al.. (2017). A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer. Targeted Oncology. 12(6). 775–785. 79 indexed citations
7.
Campo, Josep M. del, Michael J. Birrer, Craig B. Davis, et al.. (2016). A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer. Gynecologic Oncology. 142(1). 62–69. 82 indexed citations
8.
Yoshino, Takayuki, Kohei Shitara, Hiroya Taniguchi, et al.. (2015). PF-05212384 + irinotecan Phase II study in metastatic colorectal cancer (mCRC): B2151005 Japanese lead-in-cohort (J-LIC). Annals of Oncology. 26. vii72–vii72. 1 indexed citations
9.
10.
Martín, Miguel, Jacques Bonneterre, Charles E. Geyer, et al.. (2013). A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. European Journal of Cancer. 49(18). 3763–3772. 119 indexed citations
11.
Bonneterre, Jacques, CE Geyer, Yasuaki Ito, et al.. (2011). S5-7: A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs Lapatinib Plus Capecitabine for 2nd/3rd-Line Treatment of HER2+ Locally Advanced or Metastatic Breast Cancer.. Cancer Research. 71(24_Supplement). S5–7. 16 indexed citations
12.
Burstein, Harold J., Yan Sun, Luc Dirix, et al.. (2010). Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer. Journal of Clinical Oncology. 28(8). 1301–1307. 391 indexed citations
13.
Fracasso, Paula M., Ronald M. Bukowski, Thomas J. Lynch, et al.. (2009). A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors. Clinical Cancer Research. 15(7). 2552–2558. 240 indexed citations
14.
Burstein, Harold J., Yongkun Sun, Luc Dirix, et al.. (2009). Gastrointestinal and Cardiovascular Safety Profiles of Neratinib Monotherapy in Patients with Advanced ErbB2-Positive Breast Cancer.. Cancer Research. 69(24_Supplement). 5096–5096. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martina Uttenreuther‐Fischer Breakdown of academic impact, for papers by Jonathan Golas Breakdown of academic impact, for papers by Guorong Yang Breakdown of academic impact, for papers by Glenn Spehar Breakdown of academic impact, for papers by Anantbhushan Ranade Breakdown of academic impact, for papers by Kathleen Turnbull Breakdown of academic impact, for papers by Devika Gajria Breakdown of academic impact, for papers by Ruth Seggewiss‐Bernhardt Breakdown of academic impact, for papers by K. Papadopoulos Breakdown of academic impact, for papers by Maria G. Olivares
Rankless by CCL
2026